AbbVie Inc (ABBV)vsCaribou Biosciences Inc (CRBU)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
CRBU
Caribou Biosciences Inc
$1.88
-2.08%
HEALTHCARE · Cap: $205.84M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 547978% more annual revenue ($61.16B vs $11.16M). ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CRBU
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+35.1%
Fair Value
$2.45
Current Price
$1.88
$0.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Revenue surging 89.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : CRBU
The strongest argument for CRBU centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 89.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : CRBU
The primary concerns for CRBU are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while CRBU is a hypergrowth play — different risk/reward profiles.
CRBU carries more volatility with a beta of 2.46 — expect wider price swings.
CRBU is growing revenue faster at 89.7% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 33/100). CRBU offers better value entry with a 35.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Caribou Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Caribou Biosciences Inc. is a pioneering biotechnology company leveraging advanced CRISPR technology to create transformative therapies for genetic disorders and oncology. With a robust pipeline of innovative product candidates, the company is dedicated to addressing significant unmet medical needs and enhancing the landscape of precision medicine. Caribou's strategic collaborations and focus on proprietary genome-editing solutions underscore its potential to redefine treatment approaches and deliver substantial benefits to patients, positioning it as a leader in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?